About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2012 (2012), Article ID 378064, 9 pages
http://dx.doi.org/10.1155/2012/378064
Review Article

Pharmacokinetics of the Perioperative Use of Cancer Chemotherapy in Peritoneal Surface Malignancy Patients

1Department of Surgical Oncology, Oost-Limburg Hospital, Schiepse Bos 6, 3600 Genk, Belgium
2Department of Biochemistry, Faculty of Medicine, University Hasselt, 3590 Diepenbeek, Belgium
3Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA

Received 10 March 2012; Accepted 23 April 2012

Academic Editor: Yan Li

Copyright © 2012 K. Van der Speeten et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. G. Jayne, S. Fook, C. Loi, and F. Seow-Choen, “Peritoneal carcinomatosis from colorectal cancer,” British Journal of Surgery, vol. 89, no. 12, pp. 1545–1550, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. J. T. Brodsky and A. M. Cohen, “Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy,” Diseases of the Colon and Rectum, vol. 34, no. 8, pp. 723–727, 1991. View at Scopus
  3. D. Z. J. Chu, N. P. Lang, C. Thompson, P. K. Osteen, and K. C. Westbrook, “Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors,” Cancer, vol. 63, no. 2, pp. 364–367, 1989. View at Scopus
  4. B. Sadeghi, C. Arvieux, O. Glehen, et al., “Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study,” Cancer, vol. 88, no. 2, pp. 358–363, 2000.
  5. N. A. Shepherd, K. J. Baxter, and S. B. Love, “The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation,” Gastroenterology, vol. 112, no. 4, pp. 1096–1102, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Jemal, T. Murray, E. Ward, and A. Samuels, “Cancer statistics, 2005,” Ca-A Cancer Journal for Clinicians, vol. 55, pp. 10–30, 2005.
  7. A. Poveda, “Ovarian cancer treatment: what is new,” International Journal of Gynecological Cancer, vol. 13, no. 2, pp. 241–250, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. V. J. Verwaal, S. Van Ruth, E. De Bree et al., “Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer,” Journal of Clinical Oncology, vol. 21, no. 20, pp. 3737–3743, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. V. J. Verwaal, S. Bruin, H. Boot, G. van Slooten, and H. van Tinteren, “8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer,” Annals of Surgical Oncology, vol. 15, no. 9, pp. 2426–2432, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Elias, J. H. Lefevre, J. Chevalier et al., “Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 681–685, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Glehen, F. Kwiatkowski, P. H. Sugarbaker et al., “Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study,” Journal of Clinical Oncology, vol. 22, no. 16, pp. 3284–3292, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Glehen, F. Mithieux, D. Osinsky et al., “Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study,” Journal of Clinical Oncology, vol. 21, no. 5, pp. 799–806, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. T. D. Yan, D. Black, P. H. Sugarbaker et al., “A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer,” Annals of Surgical Oncology, vol. 14, no. 10, pp. 2702–2713, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Bijelic, A. Jonson, and P. H. Sugarbaker, “Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer,” Annals of Oncology, vol. 18, no. 12, pp. 1943–1950, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. T. D. Yan, L. Welch, D. Black, and P. H. Sugarbaker, “A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma,” Annals of Oncology, vol. 18, no. 5, pp. 827–834, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. T. D. Yan, D. Black, R. Savady, and P. H. Sugarbaker, “A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei,” Annals of Surgical Oncology, vol. 14, no. 2, pp. 484–492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. T. D. Yan, D. Black, R. Savady, and P. H. Sugarbaker, “Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma,” Journal of Clinical Oncology, vol. 24, no. 24, pp. 4011–4019, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Elias, O. Glehen, and F. Gilly, “Carcinose péritonéales d’origine digestive et primitive,” in Proceedings of the Rapport du 110 éme Congrès de l’AFC, Arnette : Wolters Kluwer France, 2008.
  19. R. L. Dedrick, C. E. Myers, P. M. Bungay, and V. T. Devita, “Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer,” Cancer Treatment Reports, vol. 62, no. 1, pp. 1–11, 1978. View at Scopus
  20. R. L. Dedrick, “Theoretical and experimental bases of intraperitoneal chemotherapy,” Seminars in Oncology, vol. 12, no. 3, supplement 4, pp. 1–6, 1985. View at Scopus
  21. M. A. Baron, “Structure of the intestinal peritoneum in man,” American Journal of Anatomy, vol. 69, pp. 439–497, 1941.
  22. M. Flessner, J. Henegar, S. Bigler, and L. Genous, “Is the peritoneum a significant transport barrier in peritoneal dialysis?” Peritoneal Dialysis International, vol. 23, no. 6, pp. 542–549, 2003. View at Scopus
  23. V. De Lima Vazquez, O. A. Stuart, F. Mohamed, and P. H. Sugarbaker, “Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics,” Cancer Chemotherapy and Pharmacology, vol. 52, no. 2, pp. 108–112, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Van der Speeten, O. A. Stuart, D. Chang, H. Mahteme, and P. H. Sugarbaker, “Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis,” Cancer Chemotherapy and Pharmacology, vol. 68, no. 1, pp. 147–156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Stelin and B. Rippe, “A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD,” Kidney International, vol. 38, no. 3, pp. 465–472, 1990. View at Scopus
  26. U. Bettendorf, “Lymph flow mechanism of the subperitoneal diaphragmatic lymphatics,” Lymphology, vol. 11, no. 3, pp. 111–116, 1978. View at Scopus
  27. U. Bettendorf, “Electronmicroscopic studies on the peritoneal resorption of intraperitoneally injected latex particles via the diaphragmatic lymphatics,” Lymphology, vol. 12, no. 2, pp. 66–70, 1979. View at Scopus
  28. M. H. Katz and R. M. Barone, “The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies,” Surgical Oncology Clinics of North America, vol. 12, no. 3, pp. 673–688, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. R. L. Dedrick, C. E. Myers, P. M. Bungay, and V. T. Devita, “Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer,” Cancer Treatment Reports, vol. 62, no. 1, pp. 1–11, 1978. View at Scopus
  30. M. F. Flessner, J. D. Fenstermacher, R. L. Dedrick, and R. G. Blasberg, “A distributed model of peritoneal-plasma transport: tissue concentration gradients,” American Journal of Physiology, vol. 248, no. 3, pp. F425–F435, 1985.
  31. R. L. Dedrick and M. F. Flessner, “Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure,” Journal of the National Cancer Institute, vol. 89, no. 7, pp. 480–487, 1997. View at Publisher · View at Google Scholar
  32. K. Van der Speeten, O. A. Stuart, H. Mahteme, and P. H. Sugarbaker, “A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin,” Cancer Chemotherapy and Pharmacology, vol. 63, no. 5, pp. 799–805, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Van der Speeten, O. A. Stuart, H. Mahteme, and P. H. Sugarbaker, “Pharmacology of perioperative 5-fluorouracil,” Journal of Surgical Oncology, vol. 102, no. 7, pp. 730–735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. N. R. Bachur, S. L. Gordon, M. V. Gee, and H. Kon, “NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 2, pp. 954–957, 1979. View at Scopus
  35. D. Elias, P. Dubé, F. Blot et al., “Peritoneal carcinomatosis treatment with curative intent: the Institut Gustave-Roussy experience,” European Journal of Surgical Oncology, vol. 23, no. 4, pp. 317–321, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. P. H. Sugarbaker and D. Chang, “Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy,” Annals of Surgical Oncology, vol. 6, no. 8, pp. 727–731, 1999. View at Scopus
  37. B. Barlogie, P. M. Corry, and B. Drewinko, “In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C,” Cancer Research, vol. 40, no. 4, pp. 1165–1168, 1980. View at Scopus
  38. P. H. Sugarbaker, “Successful management of microscopic residual disease in large bowel cancer,” Cancer Chemotherapy and Pharmacology, Supplement, vol. 43, pp. S15–S25, 1999. View at Scopus
  39. J. Esquivel, “Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan, and Korea,” Cancer Journal, vol. 15, no. 3, pp. 249–254, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Van Ruth, V. J. Verwaal, and F. A. N. Zoetmulder, “Pharmacokinetics of intraperitoneal mitomycin C,” Surgical Oncology Clinics of North America, vol. 12, no. 3, pp. 771–780, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. R. M. Smeenk, V. J. Verwaal, and F. A. N. Zoetmulder, “Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei—a report of 103 procedures,” European Journal of Surgical Oncology, vol. 32, no. 2, pp. 186–190, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. O. Glehen, D. Osinsky, E. Cotte et al., “Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures,” Annals of Surgical Oncology, vol. 10, no. 8, pp. 863–869, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. P. H. Sugarbaker, R. Alderman, G. Edwards et al., “Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy,” Annals of Surgical Oncology, vol. 13, no. 5, pp. 635–644, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. V. Cepeda, M. A. Fuertes, J. Castilla, C. Alonso, C. Quevedo, and J. M. Pérez, “Biochemical mechanisms of cisplatin cytotoxicity,” Anti-Cancer Agents in Medicinal Chemistry, vol. 7, no. 1, pp. 3–18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. D. K. Armstrong, B. Bundy, L. Wenzel et al., “Intraperitoneal cisplatin and paclitaxel in ovarian cancer,” New England Journal of Medicine, vol. 354, no. 1, pp. 34–43, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Markman, B. N. Bundy, D. S. Alberts et al., “Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group,” Journal of Clinical Oncology, vol. 19, no. 4, pp. 1001–1007, 2001. View at Scopus
  47. D. S. Alberts, P. Y. Liu, E. V. Hannigan et al., “Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer,” New England Journal of Medicine, vol. 335, no. 26, pp. 1950–1955, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Urano, M. Kuroda, and Y. Nishimura, “For the clinical application of thermochemotherapy given at mild temperatures,” International Journal of Hyperthermia, vol. 15, no. 2, pp. 79–107, 1999. View at Scopus
  49. J. H. Stewart IIII, P. Shen, G. Russell et al., “A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers,” Annals of Surgical Oncology, vol. 15, no. 8, pp. 2137–2145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. D. M. Elias and L. Sideris, “Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis,” Surgical Oncology Clinics of North America, vol. 12, no. 3, pp. 755–769, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Elias, M. Bonnay, J. M. Puizillou et al., “Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution,” Annals of Oncology, vol. 13, no. 2, pp. 267–272, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Jerremalm, M. Hedeland, I. Wallin, U. Bondesson, and H. Ehrsson, “Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex,” Pharmaceutical Research, vol. 21, no. 5, pp. 891–894, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. F. de Somer, W. Ceelen, J. Delanghe et al., “Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin,” Peritoneal Dialysis International, vol. 28, no. 1, pp. 61–66, 2008. View at Scopus
  54. N. Piché, F. A. Leblond, L. Sidéris et al., “Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model,” Annals of Surgery, vol. 254, no. 1, pp. 138–144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Czejka, W. Jäger, J. Schüller, et al., “Pharmacokinetics of carboplatin after intraperitoneal administration,” Archiv der Pharmazie, vol. 324, no. 3, pp. 183–184, 1991.
  56. G. Los, E. M. E. Verdegaal, P. H. A. Mutsaers, and J. G. McVie, “Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy,” Cancer Chemotherapy and Pharmacology, vol. 28, no. 3, pp. 159–165, 1991. View at Scopus
  57. T. R. Tritton, “Cell surface actions of adriamycin,” Pharmacology and Therapeutics, vol. 49, no. 3, pp. 293–309, 1991. View at Scopus
  58. P. Lane, P. Vichi, D. L. Bain, and T. R. Tritton, “Temperature dependence studies of adriamycin uptake and cytotoxicity,” Cancer Research, vol. 47, no. 15, pp. 4038–4042, 1987. View at Scopus
  59. P. Jacquet, A. Averbach, O. A. Stuart, D. Chang, and P. H. Sugarbaker, “Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model,” Cancer Chemotherapy and Pharmacology, vol. 41, no. 2, pp. 147–154, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Van der Speeten, O. A. Stuart, H. Mahteme, and P. H. Sugarbaker, “A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin,” Cancer Chemotherapy and Pharmacology, vol. 63, no. 5, pp. 799–805, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. P. B. Johansen, “Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse,” Cancer Chemotherapy and Pharmacology, vol. 5, no. 4, pp. 267–270, 1981. View at Scopus
  62. R. F. Ozols, K. R. Grotzinger, and R. I. Fisher, “Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer,” Cancer Research, vol. 39, no. 8, pp. 3202–3208, 1979. View at Scopus
  63. R. F. Ozols, G. Y. Locker, and J. H. Doroshow, “Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer,” Cancer Research, vol. 39, no. 8, pp. 3209–3214, 1979. View at Scopus
  64. R. F. Ozols, R. C. Young, and J. L. Speyer, “Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer,” Cancer Research, vol. 42, no. 10, pp. 4265–4269, 1982. View at Scopus
  65. S. R. Pestieau, O. A. Stuart, D. Chang, P. Jacquet, and P. H. Sugarbaker, “Pharmacokinetics of intraperitoneal gemcitabine in a rat model,” Tumori, vol. 84, no. 6, pp. 706–711, 1998. View at Scopus
  66. P. Sabbatini, C. Aghajanian, M. Leitao et al., “Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial,” Clinical Cancer Research, vol. 10, no. 9, pp. 2962–2967, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. R. J. Morgan Jr., T. W. Synold, B. Xi et al., “Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity,” Clinical Cancer Research, vol. 13, no. 4, pp. 1232–1237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. T. C. Gamblin, M. J. Egorin, E. G. Zuhowski et al., “Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas,” Cancer Chemotherapy and Pharmacology, vol. 62, no. 4, pp. 647–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. P. H. Sugarbaker, O. A. Stuart, and L. Bijelic, “Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data,” International Journal of Surgical Oncology, vol. 2011, Article ID 161862, 7 pages, 2011.
  70. D. S. Alberts, H. S. Chen, S. Y. Chang, and Y. M. Peng, “The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients,” Recent Results in Cancer Research, vol. 74, pp. 293–299, 1980. View at Scopus
  71. O. Glehen, O. A. Stuart, F. Mohamed, and P. H. Sugarbaker, “Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model,” Cancer Chemotherapy and Pharmacology, vol. 54, no. 1, pp. 79–84, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. P. H. Sugarbaker and O. A. Stuart, “Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan,” Cancer Chemotherapy and Pharmacology, vol. 59, no. 2, pp. 151–155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. W. P. Ceelen, L. Påhlman, and H. Mahteme, “Pharmacodynamic aspects of intraperitoneal cytotoxic therapy,” Cancer Treatment and Research, vol. 134, pp. 195–214, 2007. View at Scopus
  74. P. H. Sugarbaker, J. T. Mora, P. Carmignani, O. A. Stuart, and D. Yoo, “Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy,” Oncologist, vol. 10, no. 2, pp. 112–122, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. F. Mohamed and P. H. Sugarbaker, “Intraperitoneal taxanes,” Surgical Oncology Clinics of North America, vol. 12, no. 3, pp. 825–833, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. R. C. Rietbroek, D. M. Katschinski, M. H. E. Reijers et al., “Lack of thermal enhancement for taxanes in vitro,” International Journal of Hyperthermia, vol. 13, no. 5, pp. 525–533, 1997. View at Scopus
  77. D. S. Schrump, S. Zhai, D. M. Nguyen et al., “Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques,” Journal of Thoracic and Cardiovascular Surgery, vol. 123, no. 4, pp. 686–694, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Cividalli, G. Cruciani, E. Livdi, P. Pasqualetti, and D. Tirindelli Danesi, “Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 44, no. 2, pp. 407–412, 1999. View at Publisher · View at Google Scholar · View at Scopus
  79. F. Mohamed, O. A. Stuart, O. Glehen, M. Urano, and P. H. Sugarbaker, “Docetaxel and hyperthermia: factors that modify thermal enhancement,” Journal of Surgical Oncology, vol. 88, no. 1, pp. 14–20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. Y. Yonemura, E. Bandou, T. Sawa et al., “Neoadjuvant treatment of gastric cancer with peritoneal dissemination,” European Journal of Surgical Oncology, vol. 32, no. 6, pp. 661–665, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. E. De Bree, H. Rosing, J. H. Beijnen et al., “Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer,” Anti-Cancer Drugs, vol. 14, no. 2, pp. 103–110, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. E. DeBree, H. Rosing, D. Filis et al., “Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study,” Annals of Surgical Oncology, vol. 15, no. 4, pp. 1183–1192, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. J. L. Speyer, J. M. Collins, and R. L. Dedrick, “Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally,” Cancer Research, vol. 40, no. 3, pp. 567–572, 1980. View at Scopus
  84. P. Jacquet, A. Averbach, A. D. Stephens, O. Anthony Stuart, D. Chang, and P. H. Sugarbaker, “Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies,” Oncology, vol. 55, no. 2, pp. 130–138, 1998. View at Publisher · View at Google Scholar · View at Scopus
  85. R. B. Diasio and Z. Lu, “Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy,” Journal of Clinical Oncology, vol. 12, no. 11, pp. 2239–2242, 1994. View at Scopus
  86. C. H. Takimoto, “Antifolates in clinical development,” Seminars in Oncology, vol. 24, no. 5, supplement 18, pp. S18–S40, 1997. View at Scopus
  87. S. R. Pestieau, O. A. Stuart, and P. H. Sugarbaker, “Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model,” European Journal of Surgical Oncology, vol. 26, no. 7, pp. 696–700, 2000. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Rubin, M. Clawson, A. Planch, and Q. Jones, “Measurements of peritoneal surface area in man and rat,” American Journal of the Medical Sciences, vol. 295, no. 5, pp. 453–458, 1988. View at Scopus
  89. A. Chagnac, P. Herskovitz, T. Weinstein et al., “The peritoneal membrane in peritoneal dialysis patients: estimation of its functional surface area by applying stereologic methods to computerized tomography scans,” Journal of the American Society of Nephrology, vol. 10, no. 2, pp. 342–346, 1999. View at Scopus
  90. A. M. Albanese, E. F. Albanese, J. H. Miño et al., “Peritoneal surface area: measurements of 40 structures covered by peritoneum: correlation between total peritoneal surface area and the surface calculated by formulas,” Surgical and Radiologic Anatomy, vol. 31, no. 5, pp. 369–377, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. C. R. Rossi, M. Deraco, M. De Simone et al., “Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients,” Cancer, vol. 100, no. 9, pp. 1943–1950, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. D. Baratti, S. Kusamura, A. Martinetti et al., “Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy,” Annals of Surgical Oncology, vol. 14, no. 8, pp. 2300–2308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. O. Glehen, V. Schreiber, E. Cotte et al., “Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer,” Archives of Surgery, vol. 139, no. 1, pp. 20–26, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. F. N. Gilly, P. Y. Carry, A. C. Sayag et al., “Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis,” Hepato-Gastroenterology, vol. 41, no. 2, pp. 124–129, 1994. View at Scopus
  95. P. Keshaviah, P. F. Emerson, E. F. Vonesh, and J. C. Brandes, “Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis,” Journal of the American Society of Nephrology, vol. 4, no. 10, pp. 1820–1826, 1994. View at Scopus
  96. P. H. Sugarbaker, “Successful management of microscopic residual disease in large bowel cancer,” Cancer Chemotherapy and Pharmacology, Supplement, vol. 43, pp. S15–S25, 1999. View at Scopus
  97. J. Esquivel, “Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan, and Korea,” Cancer Journal, vol. 15, no. 3, pp. 249–254, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Van Ruth, V. J. Verwaal, and F. A. N. Zoetmulder, “Pharmacokinetics of intraperitoneal mitomycin C,” Surgical Oncology Clinics of North America, vol. 12, no. 3, pp. 771–780, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. W. P. Ceelen, L. Påhlman, and H. Mahteme, “Pharmacodynamic aspects of intraperitoneal cytotoxic therapy,” Cancer Treatment and Research, vol. 134, pp. 195–214, 2007. View at Scopus
  100. D. Elias, M. Bonnay, J. M. Puizillou et al., “Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution,” Annals of Oncology, vol. 13, no. 2, pp. 267–272, 2002. View at Publisher · View at Google Scholar · View at Scopus
  101. K. Van der Speeten, O. A. Stuart, H. Mahteme, et al., “Pharmacokinetic study of perioperative intravenous ifosfamide,” International Journal of Surgical Oncology, vol. 2011, Article ID 185092, 9 pages, 2011.